China claims its new stealth tech could evade US' proposed Golden Dome missile defense

Scientists in China have debuted a new material that could evade the proposed US missile defense system announced by President Donald Trump, dubbed the Golden Dome. Designed to evade both infrared and microwave detection, the material could be well-suited for use on high-speed aircraft and missiles.
Developed by a team led by Professor Li Qiang at Zhejiang University in Hangzhou, China, the high-performance stealth material is capable of operating across multiple detection ranges—including short-wave, mid-wave, and long-wave infrared, as well as microwaves—even at temperatures reaching 1,292 degrees Fahrenheit or 700 degree Celsius.
With detection technologies becoming increasingly advanced, stealth materials have adapted to provide multispectral protection, masking objects across wavelengths from visible light to microwaves. However, many key military systems function in high-temperature environments, testing the limits of these coatings.
High temperatures on military platforms often arise from external forces like aerodynamic heating or internal sources such as engine exhaust producing intense infrared radiation.
Traditional stealth materials can struggle under these conditions as elevated heat may compromise their effectiveness or even lead to structural damage. This has created an urgent demand for materials that combine multispectral stealth with robust thermal resistance.
This is where the new stealth material comes in offering a viable recourse. To test the material's stealth ability, the team compared it to a blackbody, which absorbs electromagnetic radiation. When heated to 1,292°F, the material's radiation temperature was about 790°F to 510°F lower than the blackbody's, the South China Morning Post writes.
The material showed a significant reduction in radiation intensity, with levels 63.6% lower than a blackbody in the mid-wave infrared (MWIR) band and 37.2% lower in the short-wave infrared (SWIR) band.
Beyond its ability to avoid detection, the material also does a great job releasing heat. When heated to 700 degrees Celsius, it gave off heat much more effectively than typical metals.
The substance's breakthrough design comes from a composite structure that combines multilayer films with a microwave metasurface. The top layer acts as a moisture barrier, while the bottom layer ensures strong adhesion to the surface beneath.
Additionally, the multilayer film is carefully laser-etched to let microwaves pass through without affecting its infrared stealth capabilities. According to the research, the device reaches a maximum operating temperature and heat dissipation performance that exceeds current leading technologies for combined high-temperature infrared and microwave stealth.
Just a few days ago, US President Donald Trump announced plans to develop the 'Golden Dome' missile defense system—the American counterpart to Israel's 'Iron Dome'—aiming to build it within the next few years. The system is intended to counter ballistic missiles, hypersonic weapons, and cruise missiles, and will reportedly include space-based tracking sensors.
If infrared tracking proves to be the primary method for the Golden Dome system to detect and intercept hypersonic weapons, materials that offer combined infrared and microwave stealth—like the one developed by Li's team—could significantly reduce the chance of detection.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Medscape

an hour ago

• Medscape

Novel GLP-1 Agonist Promotes Safe and Effective Weight Loss

Ecnoglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist, was significantly more effective than placebo for inducing weight loss in adults with overweight or obesity, based on data from more than 600 individuals, results of the SLIMMER trial showed. In addition, ecnoglutide significantly improved other key cardiometabolic risk factors including waist circumference, blood pressure, lipid profile, A1c, fasting glucose, insulin level, and uric acid, while concurrently reducing liver fat content, said study author Linong Ji, MD, of Peking University People's Hospital, Beijing, China. "These benefits position ecnoglutide as a compelling therapeutic strategy for managing clinical obesity, especially in the context of metabolic dysfunction and associated steatotic liver disease (MASLD)," he noted. The results of the phase 3 randomized trial were presented here at the American Diabetes Association (ADA) 85th Scientific Sessions and simultaneously published in The Lancet Diabetes & Endocrinology . The new drug is distinct from other GLP-1 receptor agonists in its ability to selectively induce production of cyclic adenosine monophosphate (cAMP). Unlike unbiased GLP-1 therapies, ecnoglutide selectively activates cAMP signaling pathways while minimizing β-arrestin recruitment, which may explain its enhanced effectiveness for body weight reduction and sustained metabolic effects, Ji said in an interview. Weight Loss at All Doses The researchers randomized 664 overweight and obese Chinese adults to a weekly dose of 1.2 mg, 1.8 mg, or 2.4 mg of ecnoglutide or to placebo. The coprimary endpoints were percentage change in body weight and proportion of individuals with a reduction of 5% or more in body weight after 40 weeks. The study population included adults aged 18-75 years with overweight or obesity, defined as a BMI of 28 kg/m² or higher, or 24 kg/m² or higher with at least one weight-related comorbidity (prediabetes, hypertension, hyperlipidemia, MASLD, obstructive sleep apnea syndrome, or weight-bearing joint pain), but without type 1 or 2 diabetes. The mean age of participants was 34.2 years, and half were female. Individuals in the ecnoglutide group had an average body weight loss of 9.1%, 10.9%, and 13.2% from baseline at 40 weeks at doses of 1.2 mg, 1.8 mg, and 2.4 mg, respectively, which was significantly greater at all dose levels than placebo (0.1%) ( P < 0.0001 vs placebo for all doses). In addition, significantly more patients in the ecnoglutide groups lost at least 5% of their body weight at week 40 compared to the placebo group (77%, 84%, 87%, and 16% in the 1.2-mg, 1.8-mg, 2.4-mg, and placebo groups, respectively). A key secondary efficacy endpoint was the percentage of individuals who achieved a body weight loss of at least 5% after 48 weeks; 78% to 93% of participants across the ecnoglutide groups achieved this endpoint, with the greatest changes at the higher doses. Ten individuals across the ecnoglutide groups discontinued the medication because of adverse events, the most common of which were mild-to-moderate gastrointestinal events. Treatment-emergent adverse events occurred in 93% of participants in each of the ecnoglutide groups and in 84% of the placebo group. Clinical Takeaways and Next Steps "Ecnoglutide not only represents a viable competitor in the GLP-1 analog market but also stands out with its potential to address the nonresponse limitations in obesity treatment while providing holistic metabolic benefits," Ji told Medscape Medical News . At least 10% of weight-loss patients fail to achieve clinically significant weight loss of at least 5%, he explained. Possible reasons for the lack of success include genetic polymorphisms, metabolic heterogeneity, treatment compliance, or differential receptor sensitivity, he noted. "Providing alternative treatment options with a high response rate is crucial for individuals nonresponsive to existing therapies," he said. The trial results mark a milestone in obesity therapeutics and are a significant achievement in weight management. "After 48 weeks of treatment, ecnoglutide achieved a 15.4% weight reduction, with 92.8% of patients attaining clinically meaningful weight loss," he emphasized. "Considering the high potency of ecnoglutide" and the safety data, "it might serve as a viable option for individuals who do not achieve sufficient weight reduction with existing GLP-1 receptor agonists at their approved doses or need to achieve a better reduction in body weight," he added. "I am confident and optimistic that we'll see more personalized treatment regimens for obesity." Looking ahead, patients in the ecnoglutide 1.8-mg and 2.4-mg groups continued to have weight loss at week 48 without reaching a plateau, indicating that even greater weight loss might be possible with extended ecnoglutide treatment in studies of longer duration, Ji told Medscape Medical News . "To confer the added clinical advantage, a study comparing the clinical effects of a biased GLP-1 analog with those of a pharmacokinetically-matched but balanced GLP-1 analog would be needed," he said. In an accompanying editorial, Tricia M-M Tan, PhD, of Imperial College, London, UK, wrote: "The development of biased GLP-1 receptor agonists has been met with enthusiasm from the pharmaceutical industry, but does this design feature really confer any added clinical advantage?" She agreed with Ji that a comparative study of "a biased GLP-1 analog with those of a pharmacokinetically-matched but balanced GLP-1 analog" is needed. "Only then will the clinical role of this design feature be clear," she said. However, "the clinical results from ecnoglutide are likely to be generalizable to other populations," given that the effects of GLP-1 analogs are similar when tested in patients of various ethnicities, she said, adding this may increase the global availability of GLP-1 treatments. Refining Molecules to Enhance Efficacy, Reduce Side Effects Although current therapies represent potent, effective options for obesity-modifying treatment, they have limitations, with heterogeneity of responses in terms of potency and tolerability, said Andrew Kraftson, MD, a specialist in endocrinology and internal medicine at the University of Michigan, Ann Arbor, in an interview. "Ecnoglutide continues the trend to refine these molecules to enhance efficacy and reduce side effects," he said. "When these types of peptides interact with cells, they activate certain receptors and generate a signal cascade that promotes the desired effects. However, the less specific the 'message', the less potent the signal. Additionally, side effects can be a result of the less-controlled message," he noted. As with tirzepatide, ecnoglutide was developed to produce a "biased" signal with the intent to provide greater control of the signal/message to increase the odds of weight control and reduce the odds of side effects, he explained. Although the current study was not a head-to-head comparison with other incretin mimetics, the similarity in weight loss efficacy to tirzepatide, a dual GLP-1/glucagon insulinotropic peptide agonist (GIP), was interesting and supports the biasing effect of the molecular manipulation as an effective strategy to refine incretin therapy, Kraftson told Medscape Medical News . From a clinical standpoint, the trend towards refining weight management therapy will benefit patients by expanding their options, said Kraftson. "It may also help us address the observed heterogeneity in clinical response we see in our patients and bring us closer to personalized medicine," he said. The current study's limitations, as acknowledged by the researchers, include the relatively short time period, small sample size, and lack of head-to-head comparison, said Kraftson. Additionally, the study differs from clinical practice in its dose escalation, he said. In practice, "we are not trying to get patients to a certain dose, we are trying to find the lowest, most tolerable, and sufficiently effective dose to achieve health goals; therefore, we may determine that dose titration needs to happen more slowly and/or that a low(er) dose may be sufficiently effective," he told Medscape Medical News . "The adverse event data for common gastrointestinal issues could potentially be better in clinical practice if mitigation strategies are employed," he said. "I would like to see future studies that go beyond finding the relative efficacy of doses to reporting on effective strategies for patient-dose matching."

Yahoo

3 hours ago

• Yahoo

Nvidia (NVDA) Rises After Cathie Wood Rebuilds $18.5M Stake Near All-Time High

Cathie Wood's Ark Innovation ETF (ARKK, Financials) resumed its position in Nvidia (NVDA, Financials), purchasing 128,163 shares valued at approximately $18.5 million on June 16, as the stock trades just 2.7% below its all-time high of $149.41. The move marks a reversal from 2022, when Wood exited her Nvidia position amid tightening U.S. export controls and macroeconomic concerns. She began rebuilding the stake in April following eased trade tensions and the Trump administration's decision to roll back AI-related export restrictions. Warning! GuruFocus has detected 4 Warning Signs with NVDA. The buy came shortly after Nvidia reported fiscal first-quarter results on May 28, with adjusted earnings of 96 cents per share on $44.06 billion in revenue, beating expectations of 93 cents and $43.31 billion, respectively. For the July quarter, the company forecast $45 billion in revenue, nearly $1 billion below consensus estimates, citing the impact of chip restrictions to China. Nvidia said revenue would have been about $8 billion higher without those curbs. China accounted for 13% of the company's revenue in the past fiscal year. Despite geopolitical risks, Nvidia stock is up 8.3% year to date. Wood's purchase comes as Ark Innovation ETF gains momentum, rising 15.9% in 2025 through June 18, outpacing the S&P 500's 1.9% increase. Wood's strategy remains focused on innovation platforms such as artificial intelligence, robotics, and blockchain, with Nvidia seen as a core holding aligned with those themes. Her flagship fund, however, has faced volatility, including a 60% decline in 2022 and a five-year annualized return of negative 0.3%, compared with the S&P 500's 15.7%. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Bloomberg

4 hours ago

• Bloomberg

Chinese Biotech Showcases Challenger to Eli Lilly's Obesity Drug

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new challenger to blockbusters from Novo Nordisk A/S and Eli Lilly & Co. Hangzhou Sciwind Biosciences Co. said its drug, ecnoglutide, led to more than 15% weight loss after 48 weeks when given at the highest dose. Although the trial did not compare ecnoglutide directly with existing medicines, the results were very similar to what Lilly's Zepbound showed in previous China studies, Sciwind Chief Executive Officer Hai Pan said in an interview.